Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria
Malaria Journal 20(1)
Article 2021 English
Authors
WT
Walter Taylor
RH
Richard M. Hoglund
PP
Pimnara Peerawaranun
Abstract
1 min read
In many endemic areas, Plasmodium vivax malaria is predominantly a disease of young adults and children. International recommendations for radical cure recommend fixed target doses of 0.25 or 0.5 mg/kg/day of primaquine for 14 days in glucose-6-phosphate dehydrogenase normal patients of all ages. However, for many anti-malarial drugs, including primaquine, there is evidence that children have lower exposures than adults for the same weight-adjusted dose. The aim of the study was to develop 14-day weight-based and age-based primaquine regimens against high-frequency relapsing tropical P. vivax.
Cindy S. Chu, James A Watson, Aung Pyae Phyo, Htun Htun Win, Widi Yotyingaphiram, Suradet Thinraow, Nay Lin Soe, Aye Aye Aung, Pornpimon Wilaisrisak, Kanokpich Puaprasert, Mallika Imwong, Warunee Hanpithakpong, Daniel Blessborn, Joel Tärning, Stéphane Proux, Clare Ling, François Nosten, Sir Nicholas White
Cindy S. Chu, James A Watson, Aung Pyae Phyo, Htun Htun Win, Widi Yotyingaphiram, Suradet Thinraow, Nay Lin Soe, Aye Aye Aung, Pornpimon Wilaisrisak, Kanokpich Kraft, Mallika Imwong, Warunee Hanpithakpong, Daniel Blessborn, Joel Tärning, Stéphane Proux, Clare Ling, François Nosten, Sir Nicholas White
Megha Rajasekhar, J. A. Simpson, Benedikt Ley, Peta Edler, Cindy S. Chu, Tesfay Abreha, Ghulam Rahim Awab, J. Kevin Baird, Germana Bancone, Bridget E. Barber, Matthew J. Grigg, Jimee Hwang, Harin Karunajeewa, Marcus Lacerda, Simone Ladeia-Andrade, Alejandro Llanos‐Cuentas, Sasithon Pukrittayakamee, Komal Raj Rijal, Kavitha Saravu, Inge Sutanto, Walter Taylor, Kamala Thriemer,
Discussion(0)
No comments yet. Be the first to comment.